Temozolomide chemotherapy in recurrent oligodendroglioma

被引：62
|
作者：
van den Bent, MJ
Keime-Guibert, F
Brandes, AA
Taphoorn, MJB
Kros, JM
Eskens, FALM
Carpentier, AF
机构：
[1] Univ Rotterdam Hosp, Rotterdam Canc Ctr, Dept Neurooncol, NL-3008 AE Rotterdam, Netherlands
[2] Univ Rotterdam Hosp, Rotterdam Canc Ctr, Dept Pathol, NL-3008 AE Rotterdam, Netherlands
[3] Univ Rotterdam Hosp, Rotterdam Canc Ctr, Dept Oncol, NL-3008 AE Rotterdam, Netherlands
[4] Hop La Pitie Salpetriere, Federat Neurol Marazin, Paris, France
[5] Univ Padua, Azienda Osped, Div Med Oncol, I-35100 Padua, Italy
[6] Univ Med Ctr Utrecht, Dept Neurol, Utrecht, Netherlands
来源：
NEUROLOGY | 2001年 / 57卷 / 02期
关键词：
D O I：
10.1212/WNL.57.2.340
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The authors determined the tolerance, response rate, and duration of recurrent anaplastic oligodendroglioma in 30 patients to temozolomide given orally at 150 to 200 mg/m(2) on days 1 through 5 in cycles of 28 days. Nine patients responded: 7 of 27 patients (26%) treated with temozolomide after prior PCV chemotherapy and 2 of 3 chemotherapy-naive patients (both complete response). Median time to progression in responding patients was 13 months. Temozolomide shows promise and has an acceptable safety profile in recurrent anaplastic oligodendroglial tumors. Patients not responding to PCV may respond to temozolomide.
引用
收藏
页码：340 / 342
页数：3
相关论文
共 50 条
  • [41] CHEMOTHERAPY FOR OLIGODENDROGLIOMA - PROGRESS REPORT
    CAIRNCROSS, JG
    MACDONALD, DR
    ARCHIVES OF NEUROLOGY, 1991, 48 (02) : 225 - 227
  • [42] Neoadjuvant temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma and anaplastic oligoastrocytoma with or without radiation therapy
    Mikkelsen, T
    Doyle, T
    Margolis, J
    Vick, N
    Paeologos, N
    Divine, G
    Croteau, D
    NEURO-ONCOLOGY, 2004, 6 (04) : 378 - 378
  • [43] Continuous Low-Dose Temozolomide Chemotherapy and Microvessel Density in Recurrent Glioblastoma
    Woo, Jong-Yun
    Yang, Seung Ho
    Lee, Youn Soo
    Lee, Su Youn
    Kim, Jeana
    Hong, Yong Kil
    JOURNAL OF KOREAN NEUROSURGICAL SOCIETY, 2015, 58 (05) : 426 - 431
  • [44] Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma
    Thomas, Alissa A.
    Abrey, Lauren E.
    Terziev, Robert
    Raizer, Jeffrey
    Martinez, Nina L.
    Forsyth, Peter
    Paleologos, Nina
    Matasar, Matthew
    Sauter, Craig S.
    Moskowitz, Craig
    Nimer, Stephen D.
    DeAngelis, Lisa M.
    Kaley, Thomas
    Grimm, Sean
    Louis, David N.
    Cairncross, J. Gregory
    Panageas, Katherine S.
    Briggs, Samuel
    Faivre, Geraldine
    Mohile, Nimish A.
    Mehta, Jayesh
    Jonsson, Philip
    Chakravarty, Debyani
    Gao, Jianjiong
    Schultz, Nikolaus
    Brennan, Cameron W.
    Huse, Jason T.
    Omuro, Antonio
    NEURO-ONCOLOGY, 2017, 19 (10) : 1380 - 1390
  • [45] ADJUVANT TEMOZOLOMIDE AND RADIATION FOR ANAPLASTIC OLIGODENDROGLIOMA: A SINGLE CENTER EXPERIENCE
    Haresh, K.
    Mallick, S.
    Benson, R.
    Gupta, S.
    Sharma, D.
    Julka, P. K.
    Rath, G. K.
    NEURO-ONCOLOGY, 2017, 19 : 87 - 87
  • [46] SYSTEMATIC REVIEW OF COMPARATIVE EFFICACY OF PCV AND TEMOZOLOMIDE IN THE TREATMENT OF OLIGODENDROGLIOMA
    Kazmierska, J.
    Brada, M.
    Kazmierski, M.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S81 - S81
  • [47] Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendroglioma
    Hernandez-Lain, Aurelio
    Hilario, Amaya
    Manuel Sepulveda, Juan
    Cantero, Diana
    Ramos, Ana
    Perez-Nunez, Angel
    NEUROLOGY, 2016, 87 (01) : 114 - 115
  • [48] Complete Radiologic Response in an Anaplastic Oligodendroglioma Treated with Temozolomide and Bevacizumab
    Katz, Artur
    Calabrich, Aknar
    Fernandes, Gustavo Dos Santos
    Novis, Yana Augusta Sakis
    CASE REPORTS IN ONCOLOGY, 2009, 2 (01): : 57 - 60
  • [49] PREGNANCY IN A PATIENT WITH ANAPLASTIC OLIGODENDROGLIOMA TAKING TEMOZOLOMIDE: A CASE REPORT
    Evans, Anna
    Dhall, Girish
    Finlay, Jonathan
    Wong, Kenneth
    McComb, Gordon
    NEURO-ONCOLOGY, 2010, 12 : 100 - 101
  • [50] Clinical outcome of anaplastic oligodendroglioma treated with adjuvant radiotherapy and temozolomide
    Rastogi, M.
    Gandhi, A. K.
    Khurana, R.
    Hadi, R.
    Sapru, S.
    Mishra, S. P.
    Srivastava, A. K.
    Bharati, A.
    Rath, S.
    Nanda, S. S.
    Singh, H. B.
    Kumar, S.
    Singh, N. P.
    Husain, N.
    Husain, M.
    Singh, D. K.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S464 - S464
12345